The ocular hypertension market is growing due to the rising prevalence of conditions impairing aqueous humor outflow, such as scarring and inflammation, leading to elevated intraocular pressure (IOP).

Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical ...

The design for a medical study in 1743 that was never carried out may have inspired James Lind’s groundbreaking clinical ...

As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...

The company said that all of its CONNEX trials failed to meet expectations showing no impact on patients living with ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...

On the third day, drugmakers provided updates on precision medicines for cancer and Alzheimer's, and Grail talked about the launch of a new version of the Galleri test.

BMO Capital Markets sustained its positive outlook on AbbVie Inc . (NYSE:ABBV) shares, maintaining an Outperform rating and a $208.00 price target. The firm's analyst, Evan David Seigerman, emphasized ...

The new pan-European group of 73 regulators, companies and trial sites is backed by €66.8m in funding with a six-year goal.

AbbVie (ABBV) continues to dominate the adalimumab market with 72% share in the U.S., despite biosimilar threats gaining ground. Read more here.

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...